Clinical trial NCT03593226: Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour
Official title: A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Superficial, Palpable, Unresectable/Metastatic Solid Tumour
Lead sponsor: Agalimmune Ltd.
Sponsor class: INDUSTRY
First posted: 2018-07-20
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Part 1 (Accelerated escalation): An accelerated escalation dose study designed to assess the safety and tolerability of escalating doses of AGI-134, as well as the Maximum Tolerated Dose (MTD) and the Part 2 dose (RP2D).

Part 2: This part of the study was designed to assess the safety, tolerability and anti-tumour activity of AGI-134 as a monotherapy
Primary purpose: TREATMENT

Brief summary: This study will evaluate if AGI-134 given alone is safe and tolerate in treating patients with unresectable/metastatic solid tumours.

Detailed description: Study AGI-134.FIM.101 was a Phase I/IIa, first in man (FIM), multi-center, single-arm, open-label study, designed to evaluate the safety and tolerability of escalating doses of AGI-134 as a monotherapy in unresectable/metastatic solid tumors.

The study comprised of 2 parts:

Part 1 was an accelerated escalation of the AGI-134 dose, designed to assess the safety and tolerability of AGI-134, as well as to determine the MTD (maximum tolerated dose) and recommended dose for Part 2 of the study (RP2D).

Part 2 was designed to assess the safety, tolerability and biological activity of AGI-134 at the RP2D in subjects with either deep or superficial unresectable/metastatic solid tumors.

Eligibility criteria: Inclusion Criteria

1. Adult male or female aged 18 years old or older.
2. Have a histologically or cytologically confirmed unresectable metastatic solid tumour and who have received or been intolerant to all curative treatment options and treatments demonstrated to prolong survival.
3. Subjects should have at least two measurable lesions based on RECIST v1.1 as determined by the site study team.
4. Subjects who are willing to undergo tumour biopsies, unless tumour is considered inaccessible or biopsy is otherwise considered not in the subject's best interest.
5. With sufficient tumour size for IT injection
6. Has ≥ 2 lesions:

   Has ≥1 injectable lesion which is amenable to injection and biopsy and is measurable according to RECIST v1.1.

   Has ≥1 metastatic lesion is amenable for biopsy and measurable according to RECIST v1.1
7. Evaluable Disease according to RECIST v1.1
8. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
9. Has a life expectancy \>3 months
10. Adequate organ function
11. Women of childbearing potential and all men must agree to use 2 methods of an adequate contraception
12. Subject is able and willing to comply with the requirements of the protocol.
13. Subject is able to voluntarily provide written informed consent.

Exclusion Criteria:

1. Has a disease that is suitable for therapy administered with curative intent.
2. Has any active, acute, or chronic infection(s) that are uncontrolled and/or requiring treatment, such as antibiotics
3. An active autoimmune disease that has required systemic treatment in the 2 years preceding the study
4. History of or plan for splenectomy or splenic irradiation
5. History of organ transplant or currently taking active immunosuppressive therapy
6. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
7. Has known active or chronic Hepatitis B or Hepatitis C
8. History or evidence of cancer associated with immunodeficiency states
9. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
11. Is expected to require any other form of antineoplastic therapy while on study
12. Had received live vaccines within 30 days prior to the first dose of trial treatment.
13. Has positive Immunoglobulin E (IgE) anti -Gal
14. Subject has a known allergy to alpha-Gal, such as red meat allergy, exposure to lone star tick (Amblyomma americanum), Ixodes ricinus/ holocyclus, or Cetuximab allergy
15. Has known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product
16. History or evidence of central nervous system metastases and/or carcinomatous meningitis (unless stable without treatment for at least 6 weeks and not requiring steroids)
17. Has received other experimental therapies or used an investigational device within 28 days of the first dose of treatment
18. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 14 days prior to study Day 1 or has not recovered from Adverse Event (AE) ≤ Grade 1 by treatment administered more than 14 days before first dose
19. Has had a prior anti-cancer monoclonal antibody (mAb) within 28 days prior to study Day 1 or who has not recovered from AE ≤ Grade 1 by treatment administered more than 28 days earlier.
20. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
21. Has unstable angina, new onset angina within the last 3 months, myocardial infarction within the last 6 months, uncontrolled atrial fibrillation, or current congestive heart failure with New York Heart Association Class III or higher.
22. Has a known current additional malignancy that is progressing or requires active treatment
23. O2 saturation \< 92% (on room air).
24. Has an underlying medical condition that would preclude study participation or other psychological, social or physical examination finding or a laboratory abnormality that the Investigator considers would make the subject a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.
25. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Primary outcomes:
measure: Safety and Tolerability of AGI-134 Injected Intra-tumourally (IT)
timeFrame: Up to 3 weeks after first administration of each dose level
measure: Discontinue Study Drug Due to an Adverse Events
timeFrame: Approximately 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA
state: California
city: Morristown
country: United States
facility: AHS Hospital Corp.
state: New Jersey
city: Portland
country: United States
facility: Providence Cancer Institute Franz Clinic
state: Oregon
city: Afula
country: Israel
facility: Emek Medical Center
city: Haifa
country: Israel
facility: Rambam Health Care Campus
city: Jerusalem
country: Israel
facility: Hadassah Hebrew University Medical Center
city: Ramat Gan
country: Israel
facility: Sheba Medical Center
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center
city: Birmingham
country: United Kingdom
facility: University of Birmingham
city: Edinburgh
country: United Kingdom
facility: Edinburgh Cancer Research Centre
city: Glasgow
country: United Kingdom
facility: The Beatson West of Scotland Cancer Centre
city: London
country: United Kingdom
facility: University Collage London
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
city: Oxford
country: United Kingdom
facility: Churchill Hospital
Study officials:
References: